Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease

Autores
Pérez Lloret, Santiago; Cardinali, Daniel Pedro
Año de publicación
2021
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Fil: Pérez Lloret, Santiago. Universidad Abierta Interamericana. Centro de Altos Estudios en Ciencias Humanas y de la Salud; Argentina
Fil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Pérez Lloret, Santiago. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas; Argentina
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas; Argentina
Abstract: This article discusses the role that melatonin may have in the prevention and treatment of Parkinson’s disease (PD). In parkinsonian patients circulating melatonin levels are consistently disrupted and the potential therapeutic value of melatonin on sleep disorders in PD was examined in a limited number of clinical studies using 2–5mg/ day melatonin at bedtime. The low levels of melatonin MT1 and MT2 receptor density in substantia nigra and amygdala found in PD patients supported the hypothesis that the altered sleep/wake cycle seen in PD could be due to a disrupted melatonergic system. Motor symptomatology is seen in PD patients when about 75%of the dopaminergic cells in the substantia nigra pars compacta region degenerate. Nevertheless, symptoms like rapid eye movement (REM) sleep behavior disorder (RBD), hyposmia or depression may precede the onset of motor symptoms in PD for years and are index of worse prognosis. Indeed, RBD patients may evolve to an α-synucleinopathy within 10 years of RBD onset. Daily bedtime administration of 3–12 mg of melatonin has been demonstrated effective in RDB treatment and may halt neurodegeneration to PD. In studies on animal models of PD melatonin was effective to curtail symptomatology in doses that allometrically projected to humans were in the 40–100 mg/day range, rarely employed clinically. Therefore, double-blind, placebo-controlled clinical studies are urgently needed in this respect.
Fuente
Frontiers in pharmacology Vol.12, Art.650597, 2021
Materia
MELATONINA
ENFERMEDAD DE PARKINSON
ENVEJECIMIENTO
NEURODEGENERACION
ENFERMEDADES NEURODEGENERATIVAS
TRATAMIENTO MEDICO
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/4.0/
Repositorio
Repositorio Institucional (UCA)
Institución
Pontificia Universidad Católica Argentina
OAI Identificador
oai:ucacris:123456789/11620

id RIUCA_e138e2c70d957fd3769236b4a804afc8
oai_identifier_str oai:ucacris:123456789/11620
network_acronym_str RIUCA
repository_id_str 2585
network_name_str Repositorio Institucional (UCA)
spelling Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s diseasePérez Lloret, SantiagoCardinali, Daniel PedroMELATONINAENFERMEDAD DE PARKINSONENVEJECIMIENTONEURODEGENERACIONENFERMEDADES NEURODEGENERATIVASTRATAMIENTO MEDICOFil: Pérez Lloret, Santiago. Universidad Abierta Interamericana. Centro de Altos Estudios en Ciencias Humanas y de la Salud; ArgentinaFil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Pérez Lloret, Santiago. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas; ArgentinaFil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas; ArgentinaAbstract: This article discusses the role that melatonin may have in the prevention and treatment of Parkinson’s disease (PD). In parkinsonian patients circulating melatonin levels are consistently disrupted and the potential therapeutic value of melatonin on sleep disorders in PD was examined in a limited number of clinical studies using 2–5mg/ day melatonin at bedtime. The low levels of melatonin MT1 and MT2 receptor density in substantia nigra and amygdala found in PD patients supported the hypothesis that the altered sleep/wake cycle seen in PD could be due to a disrupted melatonergic system. Motor symptomatology is seen in PD patients when about 75%of the dopaminergic cells in the substantia nigra pars compacta region degenerate. Nevertheless, symptoms like rapid eye movement (REM) sleep behavior disorder (RBD), hyposmia or depression may precede the onset of motor symptoms in PD for years and are index of worse prognosis. Indeed, RBD patients may evolve to an α-synucleinopathy within 10 years of RBD onset. Daily bedtime administration of 3–12 mg of melatonin has been demonstrated effective in RDB treatment and may halt neurodegeneration to PD. In studies on animal models of PD melatonin was effective to curtail symptomatology in doses that allometrically projected to humans were in the 40–100 mg/day range, rarely employed clinically. Therefore, double-blind, placebo-controlled clinical studies are urgently needed in this respect.Frontiers Media2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttps://repositorio.uca.edu.ar/handle/123456789/116201663-981210.3389/fphar.2021.65059733935759Pérez Lloret, S., Cardinali, D. P. Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease [en línea]. Frontiers in pharmacology. 2021, 12 (650597). doi:10.3389/fphar.2021.650597. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/11620Frontiers in pharmacology Vol.12, Art.650597, 2021reponame:Repositorio Institucional (UCA)instname:Pontificia Universidad Católica Argentinaenginfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/4.0/2025-07-03T10:57:51Zoai:ucacris:123456789/11620instacron:UCAInstitucionalhttps://repositorio.uca.edu.ar/Universidad privadaNo correspondehttps://repositorio.uca.edu.ar/oaiclaudia_fernandez@uca.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:25852025-07-03 10:57:51.664Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentinafalse
dc.title.none.fl_str_mv Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease
title Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease
spellingShingle Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease
Pérez Lloret, Santiago
MELATONINA
ENFERMEDAD DE PARKINSON
ENVEJECIMIENTO
NEURODEGENERACION
ENFERMEDADES NEURODEGENERATIVAS
TRATAMIENTO MEDICO
title_short Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease
title_full Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease
title_fullStr Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease
title_full_unstemmed Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease
title_sort Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease
dc.creator.none.fl_str_mv Pérez Lloret, Santiago
Cardinali, Daniel Pedro
author Pérez Lloret, Santiago
author_facet Pérez Lloret, Santiago
Cardinali, Daniel Pedro
author_role author
author2 Cardinali, Daniel Pedro
author2_role author
dc.subject.none.fl_str_mv MELATONINA
ENFERMEDAD DE PARKINSON
ENVEJECIMIENTO
NEURODEGENERACION
ENFERMEDADES NEURODEGENERATIVAS
TRATAMIENTO MEDICO
topic MELATONINA
ENFERMEDAD DE PARKINSON
ENVEJECIMIENTO
NEURODEGENERACION
ENFERMEDADES NEURODEGENERATIVAS
TRATAMIENTO MEDICO
dc.description.none.fl_txt_mv Fil: Pérez Lloret, Santiago. Universidad Abierta Interamericana. Centro de Altos Estudios en Ciencias Humanas y de la Salud; Argentina
Fil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
Fil: Pérez Lloret, Santiago. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas; Argentina
Fil: Cardinali, Daniel Pedro. Pontificia Universidad Católica Argentina. Facultad de Ciencias Médicas; Argentina
Abstract: This article discusses the role that melatonin may have in the prevention and treatment of Parkinson’s disease (PD). In parkinsonian patients circulating melatonin levels are consistently disrupted and the potential therapeutic value of melatonin on sleep disorders in PD was examined in a limited number of clinical studies using 2–5mg/ day melatonin at bedtime. The low levels of melatonin MT1 and MT2 receptor density in substantia nigra and amygdala found in PD patients supported the hypothesis that the altered sleep/wake cycle seen in PD could be due to a disrupted melatonergic system. Motor symptomatology is seen in PD patients when about 75%of the dopaminergic cells in the substantia nigra pars compacta region degenerate. Nevertheless, symptoms like rapid eye movement (REM) sleep behavior disorder (RBD), hyposmia or depression may precede the onset of motor symptoms in PD for years and are index of worse prognosis. Indeed, RBD patients may evolve to an α-synucleinopathy within 10 years of RBD onset. Daily bedtime administration of 3–12 mg of melatonin has been demonstrated effective in RDB treatment and may halt neurodegeneration to PD. In studies on animal models of PD melatonin was effective to curtail symptomatology in doses that allometrically projected to humans were in the 40–100 mg/day range, rarely employed clinically. Therefore, double-blind, placebo-controlled clinical studies are urgently needed in this respect.
description Fil: Pérez Lloret, Santiago. Universidad Abierta Interamericana. Centro de Altos Estudios en Ciencias Humanas y de la Salud; Argentina
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://repositorio.uca.edu.ar/handle/123456789/11620
1663-9812
10.3389/fphar.2021.650597
33935759
Pérez Lloret, S., Cardinali, D. P. Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease [en línea]. Frontiers in pharmacology. 2021, 12 (650597). doi:10.3389/fphar.2021.650597. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/11620
url https://repositorio.uca.edu.ar/handle/123456789/11620
identifier_str_mv 1663-9812
10.3389/fphar.2021.650597
33935759
Pérez Lloret, S., Cardinali, D. P. Melatonin as a chronobiotic and cytoprotective agent in Parkinson’s disease [en línea]. Frontiers in pharmacology. 2021, 12 (650597). doi:10.3389/fphar.2021.650597. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/11620
dc.language.none.fl_str_mv eng
language eng
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/4.0/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Frontiers Media
publisher.none.fl_str_mv Frontiers Media
dc.source.none.fl_str_mv Frontiers in pharmacology Vol.12, Art.650597, 2021
reponame:Repositorio Institucional (UCA)
instname:Pontificia Universidad Católica Argentina
reponame_str Repositorio Institucional (UCA)
collection Repositorio Institucional (UCA)
instname_str Pontificia Universidad Católica Argentina
repository.name.fl_str_mv Repositorio Institucional (UCA) - Pontificia Universidad Católica Argentina
repository.mail.fl_str_mv claudia_fernandez@uca.edu.ar
_version_ 1836638355570294784
score 13.13397